The cryptocurrency market has seen considerable activity involving the Injective Protocol (INJ). One significant initiative is the launch of
Injective 3.0, aimed at
reducing INJ token supply, a factor often associated with price increase due to scarcity. At the same time, key resistance was flipped and open interest has hit a three-month high, aligning with bullish indicators for the token. Further, Injective has created a considerable buzz with its Altaris upgrade launch on the mainnet. Regarding market predictions, some suggest a potential 70% surge on the horizon, with price estimates ranging up to $100 per token by respective analysts over the coming years. Even with bullish predictions, however, Injective saw a significant price slump, with a 70% drop cementing a bear trend. The recent Altaris upgrade seeks to halt this decline. In other developments,
21Shares launched an
Injective ETP with staking on Euronext, providing investors with a novel investment vehicle. Moreover, holders have added the play-2-date meme to their portfolio, hoping for considerable gains over the next month. On the negative side, some analysts suggest INJ may be overvalued, according to on-chain metrics. Despite these contrasting perspectives, INJ has shown resilience with some forecasts predicting a positive price outlook.
Injective Coin News Analytics from Wed, 06 Dec 2023 08:00:00 GMT to Wed, 02 Oct 2024 08:26:09 GMT -
Rating 2
- Innovation 5
- Information 8
- Rumor -1
